InvestorIdeas.com Newswire

Monday, June 30, 2014

Breaking Tech News: NXT-ID (OTCQB: NXTD) Resumes CNBC Ad Campaign for its Next Generation Smart Wallet, Wocket™; to Commence Week of July 7th

SHELTON, Conn. - June 30, 2014 (Investorideas.com Newswire) NXT-ID, Inc., (OTCQB: NXTD) a biometric authentication company focused on the growing m-commerce market, is pleased to announce that the second series of 30 second spots on CNBC for its next generation smart wallet, Wocket™, will begin the week of July 7th.

The new ad, "Introducing Wocket™, the Smart Wallet", will air on Squawk Box, Squawk on the Street and Street Signs. The ad focuses on the visual of a big fat bulky wallet ending up in the wrong hands with your most personal information all gone; your credit cards, your membership cards, gift cards, all gone. Replacing them is a nightmare. It then poses the question," what if there was a better way? "
Wocket™ is a smart wallet, the next evolution following the smart phone and smart watch. NXT-ID is introducing its innovative, patent-pending Wocket™ as the next natural step in the evolution of smart devices. Wocket™ is a next generation smart wallet designed to protect your identity and replace all the cards in your wallet, with no smart phone required. The Wocket works anywhere credit cards are accepted and only works with your biometric stamp of approval.
Credit, debit, ATM, loyalty, gift, ID, membership, insurance, ticket, emergency, medical, business, contacts, coupon, and virtually any card can be protected on Wocket™. More than 10,000 cards, records, coupons, etc. and 100 voice commands can also be stored on Wocket™.
Wocket™ is now available for advance ordering at www.wocketwallet.com at a price of $149.99.
The full Wocket product FAQ is available to consumers and media at http://nxt-id.com/wocket-faq/
About NXT- ID Inc. -Mobile Security for a Mobile World
NXT-ID, Inc.'s (OTCQB: NXTD) innovative MobileBio™ solution mitigates consumer risks associated with mobile computing, m-commerce and smart OS-enabled devices. The company is focused on the growing m-commerce market, launching its innovative MobileBio™ suite of biometric solutions that secure consumers' mobile platforms led by the Wocket™ ; a next generation smart wallet designed to replace all the cards in your wallet, no smart phone required. The Wocket works anywhere credit cards are accepted and only works with your biometric stamp of approval. http://www.wocketwallet.com/
NXT-ID' wholly owned subsidiary, 3D-ID LLC, is engaged in biometric identification has 22 licensed patents in the field of 3D facial recognition http://www.nxt-id.com/, http://3d-id.net/
Forward-Looking Statements for NXT-ID
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy. The Company's actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors. Such risks and uncertainties include, among other things, our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the availability of financing; the Company's ability to implement its long range business plan for various applications of its technology; the Company's ability to enter into agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the Company's technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the Company's reports filed with the Securities and Exchange Commission.
Contact:
Corporate info: info@nxt-id.com
Investor Inquiries:
Kirin Smith
ProActive Capital Group
Direct: 646 863 6519
ksmith@proactivecapital.com
Media: 800 665-0411
Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. Disclosure: As of June 2014, NXT-Id renewed for five thousand per month and average of two thousand five hundred 144 shares (cash equivalent) for news publication and marketing of Wocket smart wallet. More info: http://www.investorideas.com/About/Disclaimer.asp and http://www.investorideas.com/About/News/Clientspecifics.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

Biotech Media Advisory: GenSpera (OTCQB:GNSZ) 2014 BIO International Presentation Available

SAN ANTONIO - June 30, 2014 (Investorideas.com Biotech Newswire) GenSpera, Inc. (OTCQB:GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, releases the 2014 BIO International presentation by Chairman and CEO, Craig Dionne, PhD from the 2014 BIO International Convention held June 24th in San Diego, CA.

Dr. Dionne presented interim results from the Phase Ib and ongoing Phase II study for lead drug candidate, G-202.
Summary:
  • G-202 Data in Hepatocellular (HCC) Patients (Ph I and Ph II)
  • All patients previously progressed on, or were intolerant of, sorafenib
  • Outstanding clinical safety profile
  • Well tolerated with easily managed and predictable side effects
  • No effect on bone marrow!
  • 80% of patients with stable disease (no tumor growth) at two months
  • 50% of patients with stable disease for ≥ 4 months
  • Long-term disease stabilization (≥ 9 months) in 15% of patients
  • One patient remains on treatment > 22 months
  • End of bone pain in one patient with vertebral metastasis
The full BIO presentation is available for view at: http://www.genspera.com/press/140620_GNSZ_BIO_Presentation_June_24_2014.pdf
About GenSpera
GenSpera's technology platform combines a powerful, plant-derived cytotoxin (thapsigargin) with a prodrug delivery system that provides for the targeted release of drug candidates within a tumor. Unlike typical chemotherapeutic agents, thapsigargin results in cell death irrespective of the rate of cell division, which may provide an effective approach to kill both fast- and slow-growing cancers. GenSpera's lead drug candidate, G-202, is activated by the enzyme PSMA, which is found at high levels in the vasculature of liver and glioblastoma cancers and in the vasculature of almost all other solid tumors. G-202 is therefore expected to have potential efficacy in a wide variety of tumor types.
G-202 Phase II clinical trials are underway in both hepatocellular carcinoma and glioblastoma patients.
For more information, please visit the company's website: www.genspera.com or follow us on Twitter @GenSperaNews.
About BIO
The 2014 BIO International Convention was held June 23-26 at the San Diego Convention Center in San Diego, California.
The BIO International Convention was hosted by the Biotechnology Industry Organization (BIO). BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. http://convention.bio.org/2014/
Cautionary Statement Regarding Forward Looking Information
This news release may contain forward-looking statements. Investors are cautioned that statements in this press release regarding potential applications of GenSpera's technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties will be detailed from time to time in GenSpera's periodic reports filed with the Securities and Exchange Commission.
Contact:
Company:
Craig Dionne, PhD, CEO
GenSpera, Inc.
210-479-8112
Investors:
John Baldissera
BPC Financial Marketing
800-368-1217
Media: (800) 665 0411
Disclaimer/ Disclosure:Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp. Disclosure: Genspera (GNSZ) has engaged Investor Ideas for PR and news publication effective June 18,2014 (compensation of five thousand per month and average of eleven thousand five hundred 144 shares per month)
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

Thursday, June 26, 2014

Breaking Tech News: Analyst Update; NXT-ID Inc. (OTCQB: NXTD) Wocket Launches into Waiting Market

BOSTON - June 26, 2014 (Investorideas.com Newswire) SoundView Technology Group releases the recent research update on NXT-ID Inc. (OTCQB: NXTD) and its smart wallet, Wocket™.

Recent developments following the June 11th update include the Company has filed for a NASDAQ application and appointed a new independent Board member to satisfy that requirement for listing.
Wocket Launches into Waiting Market
Kris Tuttle & Stephen Waite – June 11, 2014
Summary: The Wocket™ was officially launched on May 28th at the Plaza Hotel in NYC. All the feedback we received from attending suggests that consumers who get a chance to see and understand it, immediately want one. It's a viable way to deliver something consumers can use as a digital wallet that is secure, private, and able to handle all their payment, identification, and loyalty needs. The Wocket is really a wallet replacement, and the functional demonstration worked very well. We'll be monitoring the progress and consumer reaction very closely over the next few months with an eye to validating our IV model, which currently suggests a stock value of $11.70/share. We have also extended our forecast to arrive at a projected IV in 2015 of $20.55.
Additional Details: As a prelude to what will be a more active marketing phase, the event included attendance by the media, investors, analysts, and Miss Universe 2012, which added a special level of energy and media attention.
In addition to elaborating on the key features, there was a live demonstration of using the Wocket to do a typical transaction by swiping the card, just as one does with a standard plastic debit or credit card.
Online preorders are available with first units shipping to consumers in September at a price of $149.99, plus some optional services for customers that require additional protection.
Wocket is NXT-ID's replacement for a conventional wallet. The heart of it is the device itself which securely stores cards digitally – that covers virtually all of the important cards consumers carry in a wallet today, including credit, debit, ATM, loyalty, gift, ID, membership, insurance, medical information, and coupons. Wocket locks a user's private information in an electronic "vault" where only an authenticated owner can authorize access to the data. The case provides some space for cash and a driver's license.
As concerns continue to mount in the U.S. and around the world about identity theft and data hacking, the timing of the launch of the Wocket helps NXT-ID channel media attention into their marketing strategy. The Wocket addresses the important issues not adequately addressed currently by smart phones and other mobile devices.
The biggest advantages are in authentication and security. The Wocket uses biometric technology to provide identity protection and security. All information used with the Wocket is encrypted by the owner's personal biometric stamp. NXT-ID is a pioneer in biometric technology, and the Wocket incorporates some of the most advanced biometric technology on the market (see our report, "Mobile Security Beyond the Password", for an in depth discussion of the technology). The device protects whatever information is stored in it so that it cannot be released to any other individual or device without the user's permission.
All payment cards and other dynamic stripe cards are swiped directly into the Wocket during the initial set-up process. Barcodes and text, such as voter's registration, loyalty and/or membership cards, may all be scanned or entered into the Wocket. All information is encrypted by the owner's personal biometric stamp and can be accessed via a low power touch screen or optionally, a voice command.
Information is placed on a tamper-proof encrypted chip inside the Wocket rather than on anywhere in the cloud. Any attempt to access the encrypted chip will result in destroying any information stored on it.
If a Wocket or Wocket card is stolen, the company can guarantee that the Wocket is worthless to anyone besides its owner. The security technology incorporated by the Wocket zeroes out any relevant information on the card dynamically after each use. Hence, the card used with the Wocket becomes a blank piece of plastic to a thief. For added peace of mind, NXT-ID will be offering customers an insurance plan for stolen, misplaced, or lost Wockets.
The Wocket can securely store up to 10,000 items including – debit/credit/loyalty/gift cards, health information, coupons, and miscellaneous records.
Battery life is expected to be one year or more, depending on frequency of use. A light will appear on the device weeks before the battery is due for replacement, so users can replace the conventional lithium ion battery that is widely available at a variety of retail stores around the world.
NXT-ID has an FAQ section on the Wocket website that addresses key questions and issues associated with the device (see: http://wocketwallet.com).
NXT-ID has started taking pre-orders for the Wocket on their website, with plans to ship the first devices in September. Unlike many digital devices on the market today, the Wocket is being manufactured in America. NXT-ID is planning a significant promotional campaign this summer to increase customer awareness and drive more pre-sales.
Sales Projections and Intrinsic Valuation: Over the past year we've seen plenty of data showing that there is strong desire for a device like the Wocket. Consumers are still waiting for an actual product to buy and use. Initial sales volumes will depend on initial orders, and initially, on the ability of NXT-ID to ramp production and manage some longer lead time components.
After a review of our current projections and intrinsic valuation (IV) model, we don't see anything that needs to be changed. However, extending the projections and model out an additional year allows us to publish a 2015 IV estimate of $20.55.
Our current estimate for sales in 2014 is 40K units, which grow fast in later years to reach nearly 1M units in 2018 and 1.5M units in 2019. These unit projections are still very low considering the small penetration rate needed to generate those numbers. If the Wocket is successful, unit growth can be much faster. Many investors were surprised by how quickly new categories like the iPad reached large numbers of units after consumer adoption. We won't have any real visibility on these longer term projections until 2015, but have a credible working forecast to start with.
Although digital currencies are not the initial focus for the Wocket, we were impressed with the figures showing consumer adoption of bitcoin wallets grew from under 500K to over 5M in one year!
Conclusion: The official launch of the Wocket has certainly increased our confidence in the IV model shown below. As consumers begin to use the device in the real world, we'll know much more.
There's huge demand to use digital payments and have a secure digital wallet that is easy to use and genuinely safe. Consumers are nearly clamoring for it. Although other companies have done Kickstarter campaigns and showed slick videos, the NXT-ID Wocket will be helping to define this market in the next few months.
The stock has been holding steady after a major post-IPO run, but our IV clearly shows there is far more to go if the Wocket is delivered on time and consumers have a good experience with it.
About SoundView Research
SoundView conducts independent research in emerging technologies. Our approach is to combine major thematic forces where technology is involved and use analysis to identify the most promising companies and investment opportunities.
Our business model is combination of advisory fees, subscriptions and shared revenue agreements. We measure our success by the quality of our analysis, accuracy of the conclusions and the size and influence of our audience. We apply our own proven approach to valuation that we call intrinsic value (IV) for informing investment decisions and optimizing portfolio management.
Full report with images and graphs: http://s3.amazonaws.com/Published_Research/NXT-ID_NXTD_Update_Note_Final_June_2014.pdf
Important Disclosures
The analysts who prepared this report certify that the content expresses accurately their personal views and opinions about the subject companies and securities. The analysts have not been and will not be receiving direct or indirect compensation for expressing the specific views or conclusions in this report.
Except where otherwise noted, clients or affiliates of SoundView Research may own positions in the securities mentioned and/or provide, have provided or may provide advisory services to some of the companies mentioned.
SoundView Research does not provide investment advice in the form of "buy," "sell," or "hold" ratings. This report is intended strictly for informational purposes. We make no claims as to the completeness or accuracy of this report although we have done our best. We do not undertake to advise you of any changes in our opinion or information contained herein.
SoundView is NOT a registered securities broker/dealer, investment bank nor investment advisory.
SoundView Technology Group does receive advisory fees, has vested interests and/or may have embedded biases in our work. However our aim is on what we call "fact-based research" and providing a balanced and informed analysis that provides illumination and insight for investors.
SoundView Research is solely responsible for all content– whether it is created for a third party, part of an advisory engagement or simply an expression of our ongoing research and analysis. We exercise final editorial control over all content produced and any mistakes, omissions or errors are our own.
Our research is distributed to institutions, investors, company managers and individuals via proprietary platforms1 and via the internet and social networks. We embrace the online community and social and professional networks to engage with colleagues, clients and investors.
SoundView maintains additional online brands for specialty research products including IPO Candy, Dealipedia and Research 2.0. We also collaborate and share with research partners like GigaOM.
Contact Information
Main Address: SoundView Technology Group, 1313 Washington St., 326, Boston MA 02118
Phone: +1-617-828-6462
Website: http://www.soundview.com
Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. Disclosure: As of June 2014, NXT-Id renewed for five thousand per month and average of two thousand five hundred 144 shares (cash equivalent) for news publication and marketing of Wocket smart wallet. More info: http://www.investorideas.com/About/Disclaimer.asp and http://www.investorideas.com/About/News/Clientspecifics.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

Wednesday, June 25, 2014

Medical Technology Breaking News: Aethlon Medical (OTCQB: AEMD) Announces Online Access to Infectious Disease and Cancer Therapy Presentation

SAN DIEGO - June 25, 2014 (Investorideas.com newswire) Aethlon Medical, Inc. (OTCBB:AEMD), the pioneer in creating medical devices that target unmet therapeutic needs in infectious disease and cancer, announced today that the presentation made by Company Chairman and CEO, Jim Joyce at The Wall Street Analyst Forum on June 19th, is now available at www.aethlonmedical.com. A link to Mr. Joyce's presentation, including both the audio and slide presentation, is accessible at http://aethlonmedical.investorroom.com/index.php?s=19. Once the page has been launched, click on the "listen to the webcast" icon.

Investorideas.com Newswire The presentation covered the following topics:
  • A status report on the first FDA approved study of Hemopurifier therapy in the United States, including Aethlon's clinical progression strategy to advance infectious disease and oncology treatment indications.
  • A review of clinical safety data and efficacy observations resulting from Hemopurifier administration to HIV and Hepatitis c (HCV) infected individuals.
  • The results of government and non-government collaborative testing programs against category "A" bioterror and pandemic threats, including pandemic influenza, dengue, ebola, pox viruses, and other viral pathogens that remain untreatable with drug or vaccine therapies.
  • The discovery that the Aethlon Hemopurifier captures tumor-secreted exosomes underlying a broad-spectrum of cancer indications and the resulting patent protection already issued to protect Aethlon's cancer treatment endeavors.
  • A review of a National Cancer Institute (NCI) sponsored publication that references Aethlon Medical as the first organization with a therapeutic candidate to address tumor-secreted exosomes.
  • A review of recent landmark discoveries that tumor-secreted exosomes suppress the immune system of cancer patients, seed the creation and spread of metastasis, promote angiogenesis, and transport PD-1, PDL-1, VEGF, CTLA-4, EGRF and other primary cancer therapeutic targets of the biopharmaceutical industry.
  • The central role of the Aethlon Hemopurifier in the rapidly emerging immuno-oncology industry, which analysts expect to grow to $35 billion per year in the near future.
  • The recent launch of Aethlon's Exosome Sciences diagnostic subsidiary, which is the first organization to demonstrate the ability to isolate exosomes that transport diagnostic biomarkers underlying alzheimer's disease (AD), chronic traumatic encephalopathy (CTE), and glioblastoma multiforme (GBM) that have crossed through blood brain barrier into the circulatory system. Thus, setting the stage for liquid biopsies that allow for the identification and monitoring of these disease conditions.
About Aethlon Medical
Aethlon Medical creates medical devices that target unmet therapeutic needs in infectious disease and cancer. The company's lead product is the Aethlon Hemopurifier®, a first-in-class device that selectively targets the rapid elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression. Exosome Sciences, Inc. is a majority owned subsidiary that is advancing exosome-based products to diagnose and monitor cancer, infectious disease and neurological disorders. Additional information can be found online at www.AethlonMedical.com or www.ExosomeSciences.com.
Certain statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, that the ESI will not be able to commercialize its future products, that the FDA will not approve the initiation of the Company's clinical programs or provide market clearance of the company's products, future human studies whether revenue or non-revenue generating of the Aethlon ADAPT™ system or the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer or hepatitis C therapies or as a standalone cancer or hepatitis C therapy, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, the ability of the Company to meet the milestones contemplated in the DARPA contract, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Contacts:
James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
Get free news alerts: Sign up here
Disclaimer/ Disclosure: Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp. Disclosure: Disclosure: AEMD subscribes to the Investorideas newswire content publishing annual program (9700 per Year, paid quarterly) for news publishing.
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

Tuesday, June 24, 2014

Breaking Biotech News: GenSpera (OTCQB:GNSZ) Releases 2014 BIO International Presentation and HCC Clinical Trial Update for G-202

SAN ANTONIO - June 24, 2014 (Investorideas.com Biotech Newswire) GenSpera, Inc. (OTCQB:GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, releases the 2014 BIO International corporate presentation. Chairman and CEO, Craig Dionne, PhD, presented the company overview and clinical trial updates for G-202 at the 2014 BIO International Convention, today, Tuesday, June 24th, at 11:15 PDT, in San Diego, CA.

Dr. Dionne presented interim results from the Phase Ib and ongoing Phase II study in hepatocellular (HCC) patients who had previously progressed on, or who were intolerant of, sorafenib. Historically, this patient population has a median time to progression of only two months when they enter subsequent clinical trials. Impressively, 80% of patients treated with G-202 had stable disease (no tumor growth) at two months and 50% of patients exhibited stable disease at 4 months on study.
Commenting on the Phase I and II data of G-202 in HCC Patients, Dr. Dionne stated, "Our lead candidate, G-202, is demonstrating better than expected clinical results and safety profile. These data are strongly encouraging and highly suggestive of clinical activity in this very challenging patient population. Relative to other drugs currently in advanced trials in HCC patients, G-202 appears to exhibit a better tolerated side effect profile and a larger subset of patients who experience disease stabilization of at least six months. Remarkably, one patient remains on treatment 22 months after initiation of treatment and another patient experienced complete remission of bone pain due to a metastatic lesion to the spinal column. As a result of these data, we are designing a randomized study as the next step toward United States Food and Drug Administration approval of G-202."
Investors can view the company presentation at the Company website: http://www.genspera.com
About GenSpera
GenSpera's technology platform combines a powerful, plant-derived cytotoxin (thapsigargin) with a prodrug delivery system that provides for the targeted release of drug candidates within a tumor. Unlike typical chemotherapeutic agents, thapsigargin results in cell death irrespective of the rate of cell division, which may provide an effective approach to kill both fast- and slow-growing cancers. GenSpera's lead drug candidate, G-202, is activated by the enzyme PSMA, which is found at high levels in the vasculature of liver and glioblastoma cancers and in the vasculature of almost all other solid tumors. G-202 is therefore expected to have potential efficacy in a wide variety of tumor types.
G-202 Phase II clinical trials are underway in both hepatocellular carcinoma and glioblastoma.
For more information, please visit the company's website: www.genspera.com or follow us on Twitter @GenSperaNews.
About BIO
The 2014 BIO International Convention is June 23-26 at the San Diego Convention Center in San Diego, California.
The BIO International Convention is hosted by the Biotechnology Industry Organization (BIO). BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. http://convention.bio.org/2014/
Cautionary Statement Regarding Forward Looking Information
This news release may contain forward-looking statements. Investors are cautioned that statements in this press release regarding potential applications of GenSpera's technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties will be detailed from time to time in GenSpera's periodic reports filed with the Securities and Exchange Commission.
Contact:
Company:
Craig Dionne, PhD, CEO
GenSpera, Inc.
210-479-8112
Investors:
John Baldissera
BPC Financial Marketing
800-368-1217
Media: (800) 665 0411
Disclaimer/ Disclosure:Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp. Disclosure: Genspera (GNSZ) has engaged Investor Ideas for PR and news publication effective June 18,2014 (compensation of five thousand per month and average of eleven thousand five hundred 144 shares per month)
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

Monday, June 23, 2014

Breaking Tech News: NXT-ID (OTCQB: NXTD) Announces Appointment of Daniel Sharkey to its Board of Directors

SHELTON, Conn. - June 23, 2014 (Investorideas.com Newswire) NXT-ID, Inc., (OTCQB: NXTD) a biometric authentication company focused on the growing m-commerce market, today announced the appointment of Daniel Sharkey as an independent director of the firm, effective immediately. Mr. Sharkey's appointment expands the Board to 4 directors, 3 of whom are independent directors. As a financial expert, Mr. Sharkey will chair the Company's Audit committee and become a member of the Compensation and Nominating committees.

"Dan's 36 years of broad experience with finance and business development for technology companies will add a valuable perspective to our Board of Directors," said Gino Pereira, Chief Executive Officer of Nxt-ID. "We appreciate his willingness to serve as a director and look forward to benefitting from his judgment and counsel. This is an important step for us following our NASDAQ application last week."
Dan Sharkey was Executive Vice President of Business Development of ATMI, a publicly traded semi-conductor company from 2007 to 2014, and was responsible for expanding ATMI markets and long-term growth potential by identifying and delivering new strategic and product opportunities. Mr. Sharkey joined ATMI as Chief Financial Officer in April 1990 and continued in that position with the additional responsibilities as Treasurer and Secretary until 2007. ATMI was sold to Entegris in 2014 for $1.15 billion.
Before joining ATMI, Mr. Sharkey was Vice President of Finance for Adage, Inc., a publicly traded computer graphics manufacturer, from 1987-1990. From 1983-1987, he was Corporate Controller for CGX Corporation a venture capital-backed, privately held computer graphics manufacturer that merged with Adage, Inc. in 1987. From 1978 to 1983, Mr. Sharkey worked as a Certified Public Accountant in the Boston office of KPMG Peat Marwick.
Mr. Sharkey earned a Bachelor of Arts degree in Economics and Accounting from the College of the Holy Cross in Worcester, Massachusetts.
NXT-ID is preparing for shipment of its Wocket™ SmartWallet in September 2014. Wocket™ is a smart wallet in the same vein as the smart phone and smart watch. NXT-ID is introducing its innovative, patent-pending Wocket™ as the next natural step in the evolution of smart devices. Wocket™ is a next generation smart wallet designed to replace all the cards in your wallet, with no smart phone required. The Wocket works anywhere credit cards are accepted and only works with your biometric stamp of approval.
Credit, debit, ATM, loyalty, gift, ID, membership, insurance, ticket, emergency, medical, business, contacts, coupon, and virtually any card can be protected on Wocket™. More than 10,000 cards, records, coupons, etc. can also be stored on Wocket™.
The Wocket retails for $149.99. Advance order a Wocket at: http://www.wocketwallet.com
About NXT- ID Inc. - Mobile Security for a Mobile World
NXT-ID, Inc.'s (OTCQB: NXTD) innovative MobileBio™ solution mitigates consumer risks associated with mobile computing, m-commerce and smart OS-enabled devices. The company is focused on the growing m-commerce market, launching its innovative MobileBio™ suite of biometric solutions that secure consumers' mobile platforms led by the Wocket™ ; a next generation smart wallet designed to replace all the cards in your wallet, no smart phone required. The Wocket works anywhere credit cards are accepted and only works with your biometric stamp of approval. http://www.wocketwallet.com
NXT-ID's wholly owned subsidiary, 3D-ID LLC, is engaged in biometric identification and has 22 licensed patents in the field of 3D facial recognition http://www.nxt-id.com/, http://3d-id.net/
Forward-Looking Statements for NXT-ID
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy. The Company's actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors. Such risks and uncertainties include, among other things, our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the availability of financing; the Company's ability to implement its long range business plan for various applications of its technology; the Company's ability to enter into agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the Company's technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the Company's reports filed with the Securities and Exchange Commission.
Contact:
Corporate info: info@nxt-id.com
Investor Inquiries:
Kirin Smith
ProActive Capital Group
Direct: 646 863 6519
ksmith@proactivecapital.com
Media: 800 665-0411
SOURCE: NXT-ID, Inc.

Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. Disclosure: As of June 2014, NXT-Id renewed for five thousand per month and average of two thousand five hundred 144 shares (cash equivalent) for news publication and marketing of Wocket smart wallet. More info: http://www.investorideas.com/About/Disclaimer.asp and http://www.investorideas.com/About/News/Clientspecifics.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

Breaking Biotech News: GenSpera, Inc. (OTCQB:GNSZ) Releases Updated Corporate Video: "GenSpera has targeted its active ingredient thapsigargin to kill only the cells we select: cancer"

SAN ANTONIO - June 23, 2014 (Investorideas.com Biotech Newswire) GenSpera, Inc. (OTCQB:GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, releases the updated corporate video explaining its lead drug candidate, G-202.

The video explains, "The thapsigargin plant, a weed that grows abundantly in the Mediterranean, kills by disruption of the calcium balance in cells, all cells. Now, Genspera has targeted its active ingredient thapsigargin, to kill only the cells we select: cancer."
Chairman and CEO, Craig Dionne, PhD. says, "We have taken the powerful toxin thapsigargin and found a way to keep it inactive until it finds the cells it has been programmed to seek. Then it releases its active ingredient and destroys all of the targeted cells."
In the case of GenSpera's first drug, G-202, this target is PSMA, an enzyme which is only found on the walls of the blood vessels that feed cancer tumors, regardless of the type of cancer.
See the Video: http://youtu.be/jULjEul-mBk
Chairman and CEO, Craig Dionne, PhD., will be presenting at the 2014 BIO International Convention on Tuesday, June 24th at 11:15 PDT in San Diego, CA, where he will be providing an update on G-202. The Company's BIO presentation will be available on June 24th to investors.
About GenSpera
GenSpera's technology platform combines a powerful, plant-derived cytotoxin (thapsigargin) with a prodrug delivery system that provides for the targeted release of drug candidates within a tumor. Unlike typical chemotherapeutic agents, thapsigargin results in cell death irrespective of the rate of cell division, which may provide an effective approach to kill both fast- and slow-growing cancers. GenSpera's lead drug candidate, G-202, is activated by the enzyme PSMA, which is found at high levels in the vasculature of liver and glioblastoma cancers and in the vasculature of almost all other solid tumors. G-202 is therefore expected to have potential efficacy in a wide variety of tumor types.
G-202 Phase II clinical trials are underway in both hepatocellular carcinoma and glioblastoma.
For more information, please visit the company's website: www.genspera.com or follow us on Twitter @GenSperaNews.
Cautionary Statement Regarding Forward Looking Information
This news release may contain forward-looking statements. Investors are cautioned that statements in this press release regarding potential applications of GenSpera's technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties will be detailed from time to time in GenSpera's periodic reports filed with the Securities and Exchange Commission.
Contact:
Company:
GenSpera, Inc.
Craig Dionne, PhD, 210-479-8112
CEO
Investors:
BPC Financial Marketing
John Baldissera, 800-368-1217
Disclaimer/ Disclosure:Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp. Disclosure: Genspera (GNSZ) has engaged Investor Ideas for PR and news publication effective June 18,2014 (compensation of five thousand per month and average of eleven thousand five hundred 144 shares per month)
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

President and CEO of UMeWorld (UMEWF) Discusses Their Online Video Platform in China and Recent SI Partnership with China Mobile (CHL)

New York, NY - Point Roberts, WA - June 23, 2014 (Investorideas.com newswire) Investorideas.com, a global news source covering leading sectors including tech issues an exclusive Q&A with Mr. Michael Lee, President and CEO of UMeWorld(OTC: UMEWF). Mr. Lee discusses the company’s emerging online user generated video platform in China and the recent announcement of its partnership with China Mobile Limited (NYSE:CHL), (HKEx Stock Code: 00941).

Q: Investorideas.com
For readers that don’t know your company, can you give a brief overview of the divisions and your current focus?
A: President and CEO Michael Lee
UMeWorld is an online video and education internet company in China. Currently, UMeWorld operates UMeLook.com, an online video platform focused on bringing foreign video content to China and UMFun.com, an online K-12 adaptive learning education platform which provides learning & educational assessment services for K-12 students. Our mission is to facilitate interaction between people -"You" and "Me," through our UMeLook and UMFun online platforms-and drive synergies between the two operating segments.
Q: Investorideas.com
You just announced an SI partnership withChina Mobile Limited’s educational platform. Can you explain how that will unfold and what is the significance * to your company?
A: President and CEO Michael Lee
This is a major milestone and game-changing event for us. An SI (Service Integrator) partnership such as this, is at the highest level of collaboration for value added services. As such, it is a very strong endorsement for our company. It is a testament to our competence and a recognition of the quality of our products. China Mobile is the world’s largest mobile services provider by subscriber base, serving over 760 million customers. This SI partnership accelerates our market penetration and will provide a substantial revenue stream for our company in 2015 and beyond. We are now working diligently with China Mobile to bring UMFun to its’ millions of customers.  
Q: Investorideas.com
With your online video content platform and educational divisions, which areas do you see the most significance in long term growth and why?
A: President and CEO Michael Lee
I believe both divisions are well positioned for long term growth and our objective is to drive synergies between the two operating segments.
UMeLook is a niche market player that does not compete with local video platforms such as Youku & Ku6; most local video platforms are focused on local content. There is no competition from YouTube, Dailymotion or Vimeo, as all are blocked in China. China has 570 million online video viewers and expected to grow to 716 million by 2016.
The K-12 education system in China is the largest in the world. According to Statistics China released by the China Press and Publications Administration, it is indicated that 154,526 types of publications went to press nationally in 2011, including 63.1 million books. Total sales were 966.82 billion RMB (US$154 billion) -52.9% and 37.39% being primary and secondary school materials respectively. The potential market for related digital services such as UMFun is so huge that the Chinese K-12 online education market is called the last piece of meat on the table in the worldwide digital media space.
Q: Investorideas.com
In closing, do you think there are similar opportunities like the recent one with China Mobile or are you working with them exclusively?
A: President and CEO Michael Lee
* The China Mobile deal is just the beg inning. We do expect and are well positioned to do a similar deal with China Telecom and China Union Telecom; each of these companies serving 300 million customers respectively. Our products are user friendly and can only enhance the service providers.
About UMeWorld (UMEWF)
UMeWorld's mission is to facilitate the interaction between people -- "You" and "Me," -- through its digital platforms. UMeLook.com, an online video platform focused on bringing foreign video content to China, is deployed through a sophisticated CDN (Content Delivery Network) with broad coverage throughout mainland China. UMeLook.com plans to be the go to source of foreign video content for the Chinese viewer across any Internet-enabled device in China. UMFun™ is a cost effective, engaging and fun to use assessment and tutoring platform that can intelligently analyze and adapt to a student’s performance and personalizes the delivery of proprietary educational items according to the student’s learning needs. http://www.umeworld.com/
SEC Filings: http://www.umeworld.com/SECFilings/AllSECFilings/
About China Mobile Limited (NYSE:CHL), (HKEx Stock Code: 00941)
China Mobile Limited, an investment holding company, provides mobile telecommunications and related services in Mainland China and Hong Kong.http://www.chinamobileltd.com
UMEWF Contact:
UMeWorld Limited
Ruby Hui, 852-2824-8716
info@UMeWorld.com
About InvestorIdeas.com:
InvestorIdeas.com is a global news source for investors following leading business sectors including biotech, tech, mining, mobile, energy, water, defense and security, renewable energy, food and beverage stocks and Latin American stocks.
Follow Investorideas.com on Twitter   http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook   http://www.facebook.com/Investorideas
Sign up for our free news alerts
http://www.investorideas.com/Resources/Newsletter.asp
Become an Investorideas.com Member and use our online stock directories to research stocks - including biometric and mobile payment stocks http://www.investorideas.com/membership/
Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp. Disclosure: UMEWF has engaged Investor Ideas for one month for news publication and PR (one thousand dollars)
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.
800-665-0411 - Source - www.Investorideas.com

Thursday, June 19, 2014

Breaking Tech News: NXT-ID (OTCQB: NXTD) to Accept Bitcoin for Wocket Wallet Orders

SHELTON, CT - June 19, 2014 (Investorideas.com Newswire) NXT-ID, Inc., (OTCQB: NXTD) a biometric authentication company focused on the growing m-commerce market, today announced that it will begin accepting Bitcoin for Wocket™ purchases. In the next few days customers will be able to pay for pre-orders with Bitcoin as well as Visa, Mastercard, American Express, Discover and Paypal.

Bitcoin is being increasingly accepted at forward thinking companies such as Virgin Atlantic, Expedia, Tesla, Zynga and Tiger Direct.
Mr. Gino Pereira, CEO of NXT-ID, Inc. said, "It is important that, as a leading company in the modernization and digitization of the physical wallet, we support digital currencies such as Bitcoin. Peer to peer transactions will be a significant component of the payment industry going forward. NXT-ID intends to participate in this segment not only as a retailer accepting digital currencies, but also as an enabler of peer to peer transactions with encrypted communication in future versions of Wocket."
Wocket™ is a smart wallet in the same vein as the smart phone and smart watch. NXT-ID is introducing its innovative, patent-pending Wocket™ as the next natural step in the evolution of smart devices. Wocket™ is a next generation smart wallet designed to replace all the cards in your wallet, with no smart phone required. The Wocket works anywhere credit cards are accepted and only works with your biometric stamp of approval.
Credit, debit, ATM, loyalty, gift, ID, membership, insurance, ticket, emergency, medical, business, contacts, coupon, and virtually any card can be protected on Wocket™. More than 10,000 cards, records, coupons, etc. can also be stored on Wocket™.
The Wocket retails for $149.99. Advance order a Wocket at: http://www.wocketwallet.com/
About NXT- ID Inc. - Mobile Security for a Mobile World
NXT-ID, Inc.'s (OTCQB: NXTD) innovative MobileBio™ solution mitigates consumer risks associated with mobile computing, m-commerce and smart OS-enabled devices. The company is focused on the growing m-commerce market, launching its innovative MobileBio™ suite of biometric solutions that secure consumers' mobile platforms led by the Wocket™ ; a next generation smart wallet designed to replace all the cards in your wallet, no smart phone required. The Wocket works anywhere credit cards are accepted and only works with your biometric stamp of approval. http://www.thewocket.com/, http://www.wocketwallet.com/
NXT-ID' wholly owned subsidiary, 3D-ID LLC, is engaged in biometric identification has 22 licensed patents in the field of 3D facial recognition http://www.nxt-id.com/, http://3d-id.net/
Forward-Looking Statements for NXT-ID
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy. The Company's actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors. Such risks and uncertainties include, among other things, our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the availability of financing; the Company's ability to implement its long range business plan for various applications of its technology; the Company's ability to enter into agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the Company's technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the Company's reports filed with the Securities and Exchange Commission.
Contact:
Corporate info: info@nxt-id.com
Investor Inquiries:
Kirin Smith
ProActive Capital Group
Direct: 646 863 6519
ksmith@proactivecapital.com
Media: 800 665-0411

Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. Disclosure: As of June 2014, NXT-Id renewed for five thousand per month and average of two thousand five hundred 144 shares (cash equivalent) for news publication and marketing of Wocket smart wallet. More info: http://www.investorideas.com/About/Disclaimer.asp and http://www.investorideas.com/About/News/Clientspecifics.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.